Abbott’s deal to acquire Exact Sciences is expected to close on Monday after regulatory clearances.
This transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott’s 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share by approximately $0.20.
“The addition of Exact Sciences enhances Abbott’s growth profile and strengthens our leadership in diagnostics,” Robert B. Ford, chairman and chief executive officer of Abbott, said in a statement. “This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health.”
Exact Sciences is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor recurrence.
Cancer screening and precision oncology diagnostics in the U.S. is a $60 billion business.
Exact Sciences is known for product offerings like the Cologuard test, a market-leading noninvasive colorectal cancer screening option.
